Compare · JNJ vs LIXT
JNJ vs LIXT
Side-by-side comparison of Johnson & Johnson (JNJ) and Lixte Biotechnology Holdings Inc. (LIXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and LIXT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ carries a market cap of $680.19B.
- JNJ has hit the wire 14 times in the past 4 weeks while LIXT has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 0 for LIXT).
- Company
- Johnson & Johnson
- Lixte Biotechnology Holdings Inc.
- Price
- -
- -
- Market cap
- $680.19B
- -
- 1M return
- +10.60%
- -
- 1Y return
- +41.60%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York.
Latest JNJ
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- EVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)
- FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Latest LIXT
- SEC Form 8-K filed by Lixte Biotechnology Holdings Inc.
- Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Amendment: Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 10-Q filed by Lixte Biotechnology Holdings Inc.
- Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Lixte Biotechnology Holdings Inc.
- SEC Form PRE 14A filed by Lixte Biotechnology Holdings Inc.
- Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD
- LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD